CARMIEL, Israel (AP) _ Protalix BioTherapeutics Inc. (PLX) on Wednesday reported a loss of $15.5 million in its third quarter.
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents.
The drug developer posted revenue of $663,000 in the period.
The company's shares closed at 49 cents. A year ago, they were trading at 76 cents.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PLX at https://www.zacks.com/ap/PLX